Wealthfront Advisers LLC Buys Shares of 15,136 Dynavax Technologies Co. (NASDAQ:DVAX)

Wealthfront Advisers LLC bought a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 15,136 shares of the biopharmaceutical company’s stock, valued at approximately $193,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DVAX. Smartleaf Asset Management LLC increased its stake in shares of Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,034 shares during the last quarter. US Bancorp DE increased its stake in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,034 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Dynavax Technologies during the 4th quarter valued at about $71,000. Finally, Nisa Investment Advisors LLC increased its stake in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,076 shares during the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on DVAX. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th.

Dynavax Technologies Stock Down 1.7 %

DVAX opened at $13.63 on Tuesday. The firm has a 50 day moving average price of $13.13 and a 200 day moving average price of $12.33. The company has a market cap of $1.69 billion, a PE ratio of 75.72 and a beta of 1.23. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.05. The firm had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Sell-side analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.